Annika Filip
Research
I am interested in the interplay of post-translational modifications (PTMs), specifically SUMOylation and methylation, in the context of immunotherapies. Both methylation and SUMOylation regulate a broad spectrum of immune system processes, including cytokine signaling. By altering these PTM’s, we are hoping to rewire transcriptional programs for both T cells and tumor cells, to overcome transcriptional blocks and ultimately improve the effectiveness of TCR therapies for hematological malignancies.
Curriculum vitae
I completed my M.Sc. of Molecular Biomedicine at the Heinrich-Heine-Universität Düsseldorf, where I studied and characterized the pre-leukemic state of ETV6::RUNX1+ B-ALL in the lab of Dr. Ute Fischer in the Pediatric Hematology Department of the UKD. I later joined the Müschen lab at the Yale Center for Molecular and Cellular Oncology as a post-graduate research associate, where I focused on genetically engineered models of malignant B cell lymphopoiesis both in vitro and in vivo. I then joined the Cancer Immunology Department at Boehringer Ingelheim Pharmaceuticals, where I designed and generated genetically engineered in vitro models for various pipeline projects. In February 2025, I joined the SUMO lab as a PhD candidate under the supervision of Alfred Vertegaal and Mirjam Heemskerk (Experimental Hematology).
